MedTrace Logo

A Safety/Efficacy Trial of Zonisamide for Essential Tremor

NCT00223743 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2012-06-22

No results posted yet for this study

Summary

The purpose of this pilot study is to obtain information whether the medication zonisamide reduces tremor in persons with essential tremor and is well tolerated.

Conditions

Interventions

DRUG

Zonisamide

study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.

Sponsors & Collaborators

  • Ralph M. Parsons Foundation

    collaborator OTHER

  • VA Greater Los Angeles Healthcare System

    lead FED

Principal Investigators

  • Adrian Handforth, M.D. · Veterans Affairs Greater Los Angeles

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00223743 on ClinicalTrials.gov